VIDEO: Reforms at the FDA Level
by Ha Kung Wong
November 14, 2017
In response to internal FDA reforms, Ha Kung Wong, Molly Burich, Amanda Forys, and Angus Worthing share their expectations concerning review and approval timelines for biosimilar products that are safe, effective, and priced competitively within the market as part of the The Center for Biosimilars™ Peer Exchange®.
Ha Kung Wong
has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders. He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios. Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry.